I tried popular weight loss diet for two weeks heres the surprising things I learned… – The US Sun

WE'RE told many things when it comes to food: dont skip meals, but skip snacks, eat intuitively, but not too much

It can all get very confusing! So its easy to see how the simplicity of intermittent fasting where, sticking to your usual calorie intake, you restrict eating to certain times of the day can seem attractive.

2

Even more so if youre keen to lose weight, which lots of us are this summer saw a whopping 1,100% increase in Google searches for: How to lose stubborn belly fat.

According to research by Harvard School of Public Health, intermittent fasting sees a typical weight loss of 7-11lb when followed for 10 weeks.

Ten weeks seemed a bit much for my first try, but would two make a difference to my health, happiness and the number on my bathroom scales?

A drop in insulin during fasting is shown to facilitate fat burning. Growth hormone levels may also increase, which can support fat burning and muscle formation, says nutritionist Rob Hobson, co-author of The Detox Kitchen Bible.

Fasting also appears to improve insulin sensitivity, which helps maintain healthy blood sugar levels and reduce the risk of type 2 diabetes, says Rob.

Studies have also found fasting can help ward off arthritis*, chronic pain** and high blood pressure***, while the increased levels of healthy gut bacteria that come from intermittent fasting aid digestion, and a happy gut is linked to improved mental health.

So far, fasting almost sounds too good to be true, and Im not one for calorie-counting either, which makes it even more appealing.

As someone who suffers from irritable bowel syndrome, cutting down my window of eating, avoiding late-night snacking and allowing my digestive system time to work its magic also seemed like something I couldbenefit from.

I opt for the 16:8 diet, which involves eating within an eight-hour window, then fasting for 16 hours (other variations include 14:10, and 5:2, in which you fast for two days in a week).

In theory, you sleep through the bulk of the 16 hours, setting your eating window as 9am-5pm or 12pm-8pm, so you can fit in your usual breakfast, lunch and dinner times.

But you can set any hours that suit you. During week one, it was difficult to get a handle on my fasting window.

Due to a busy schedule, I had to alternate the hours I ate to avoid being antisocial, which at times meant not eating for a whole 24 hours.

As a result, during the eight-hour window I could eat, I was gorging on everything I could get my hands on, which was counter-productive.

There is huge scope for giving in to hunger, says Rob, which could result in binge-eating and unhealthy snacking.

To keep energy levels up, I was snacking a lot on apples, as theyre said to curb hunger pangs, and bananas, but also crisps and biscuits.

I was so tired and irritable, getting annoyed over silly things, such as my boyfriend eating when I couldnt.

I even cancelled plans because I couldnt face doing anything.

On the plus side, by the end of the first week, Id noticed my bowel movements had become more regular, because my body had time to actually digest what I was eating and, as a result, I felt less bloated.

Even still, the number on the scales hadnt budged.

2

For week two, I wanted to be more mindful about what and when I was eating.

I set my feasting window from 12pm-8pm, stuck to it and squeezed in three meals. It was tough though.

Rob told me to increase my fibre and protein intake to ward off hunger pangs.

Breakfast (eaten more around lunchtime) was peanut butter on toast, overnight oats or Greek yoghurt and fruit.

Id try to make a falafel wrap for lunch, and for dinner found myself having carbs like potatoes or pasta to keep me fuller for longer.

When I ate light options, such as salmon and broccoli, Id wake up starving in the night.

I assumed fasting meant avoiding tea, coffee or other drinks that help take the edge off tummy rumbles, but you dont have to rule them out.

In fact, Rob suggests getting creative with your options. You are going to get hungry, so stock up on miso soup and low-calorie hot chocolate to have during your fasting window, he says.

I upped my fluids throughout the day and realised that when I thought I was hungry, sometimes I was actually just dehydrated.

Although I didnt drop any weight during my fortnight on the 16:8 plan, at times I did feel less bloated and could fit comfortably into a tighter skirt than usual.

I also drank more water, became mindful about what I was eating to stay energised and I ditched evening snacking (which is a real culprit when it comes to piling on the pounds).

However, I underestimated how hard fasting would be.

Cavemen were pros at it, fasting until they caught and killed their next meal, and some religions regularly feature periods of fasting, so its doable, but my concentration, tolerance level and sleep suffered drastically, plus I ended up avoiding exercise because I felt too weak.

Rob suggests exercising between meals so you are fuelled up with the energy and protein to promote muscle recovery, but I found it exhausting.

Logistically, fasting is tricky. When I meal-prepped in advance, it felt easier but knowing those healthy meals were waiting for me in the fridge, Id want to eat them sooner, which made it even more difficult to stick to my feasting window.

For me, fasting for weight loss just didnt feel sustainable for more than a couple of weeks even if it did kick my late-night snacking habits into touch!

Your Feasting-Window Meal Plan

Follow Rob Hobsons menu to keep you from reaching for the snacks

Breakfast

Porridge with milk and topped with honey, nuts, seeds, cinnamon and fruit. Stir in yoghurt for extra protein and calcium.

Lunch

Wholemeal wrap or pitta bread, filled with salad and a protein (meat, fish, tofu or cheese). Add a handful of grain, such as brown rice or quinoa, and mashed avocado.

Dinner

Grain-based salad with veg, a protein and healthy fats (avocado, nuts, seeds). Dress the salad with olive oil and lemon juice. Follow with a dessert of yoghurt and fruit.

Originally posted here:

I tried popular weight loss diet for two weeks heres the surprising things I learned... - The US Sun

Hindus of Greater Houston honors 75 youth for commitment to community – newsindiatimes.com

75 youth awardees pose for a photo at the Sept. 10, 2022, event in Houston hosted by the Hindus of Greater Houston. Photo: HGH

At an event in Houston Sept. 10, 2022, hosted by Hindus of Greater Houston, HGH, 75 youth were recognized and honored for their strong sense of community, fostering conversations about Indian culture, and inspiring the next generation of leaders with their contributions. The event was held at the newly renovated auditorium at Sri Meenakshi Temple which was filled to capacity with more than 500 people.

Past President of HGH Partha Krishnaswamy came up with the idea of awarding 75 Hindu youth this year to commemorate Indias Azadi ka Amrit Mahotsav (75 years of Indias Independence), a press release from Krishnaswamy said. It was approved by the HGH team.

More than 44 organizations participated, 75 awardees were selected and included those of Caucasian, African American, Caribbean, Nepali, and Indo-American origin. The event was attended by representatives from participating organizations, donors, HGH Advisory board members, community leaders and distinguished guests, the press release said.

- ADVERTISEMENT -

A lamplighting cermony kickstarted the evening which was replete with insights, inspiration, and practical takeaways. Beth Kulkarni, HGH and Hindu Temple of The Woodlands founding member, highlighted the organizations prominent role in encouraging and mentoring the youth.

Keynote speaker Partho Ghosh offered a transformative way of thinking with his seven-point vision to make the world a better place, and also dwelt on how Vedanta philosophys tenets can drive better leaders.

Young speakers Somansh Agarwal and Naisargi Jaiswal of the National President of Hindu Students Association shared pointers on ways to engage with others in promoting Indian culture and traditions and how the youth could take these practices forward in their colleges.

Also part of the evening was a Kathak performance from the Shivangini Academy of Performing Arts and a Bharatanatyam Thillana by the Abhinaya School of Performing Arts.

Deputy Consul General of India in Houston Sandeep Choudhary congratulated the awardees and spoke briefly of the importance of connectivity of the youth awardees with those in India.

Interfaith Ministry of Greater Houston Program Manager Kim Mabry thanked HGH for inviting the Interfaith Ministries to the Hindu Youth Awards ceremony, describing it as a beautiful display of the life, art, and culture of the Hindu community of Houston.

A surprise 75-item dessert station accompanied the dinner. The sweets were prepared by BAPS Shayona and Bombay Sweets. Nalini Kannan of Decor One decorated the dessert station in tune with the theme of the evening.

Read more:

Hindus of Greater Houston honors 75 youth for commitment to community - newsindiatimes.com

Grand Forks instructor is ‘Teacher of the Year’ – Prairie Public Broadcasting

An English Language teacher from Red River Hgh School in Grand Forks has been named the 2023 North Dakota Teacher of the Year.

Ivana Todorovic is a native of Bosnia, who came to Grand Forks in 1995. She teaches students who are not fluent in English, or are learning the language for the first time. And she has been teaching for 17 years.

Todorovic received the honor at a state capitol ceremony in Bismarck. In her remarks, she encouraged teachers to continue to make a difference.

"Don't ever forget that you do make a difference in your students' lives," Todorovic said. "And this itself gives us energy, inspiration and passion to continue our journey as teachers and public servants of this great country and state. And rememeber we may not have it all together, but together, we have it all."

Todorovic was one of four finalists for the award. The others were Abby DuBord, a first grade teacher at Elk Ridge Elementary School in Bismarck; Megan Margerum, a third grade teacher at Northern Cass Public School; and Megan Wald, a business instructor at Linton High School.

More:

Grand Forks instructor is 'Teacher of the Year' - Prairie Public Broadcasting

Anti Aging Products and Therapies Market rocket up to USD 3.3 Billion by 2029 at a 8% CAGR Check Industry Share, Growth, Analysis, Value, Statistics -…

Luton, Bedfordshire, United Kingdom, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Anti-Aging Products and Therapies Market.

The market for Anti Aging Products and Therapies is anticipated to grow at a CAGR of 8% over the course of the forecast period, reaching USD 3.3 billion by 2029.

Anti Aging Products and Therapies Market

The market for Anti Aging Products and Therapies will expand strongly during the anticipated period due to the growth in aging populations in numerous developed and developing nations. The demand for Anti Aging therapies and ultimately Anti Aging products will rise as medical tourism for aesthetic procedures and new Anti Aging technology are developed.

Aging is a maturing phase that involves a decline in stamina, strength, agility, speed, basal metabolism, acute hearing, and sexual activity. The bones are more fragile, the teeth shed easily, and the skin is drier. Aging skin is mainly associated with a sagging face, in which deeper tissues such as subjacent soft tissue and structural landmarks lose their resiliency. Anti Aging is a process of limiting or slowing these changes through various products and therapies.

Although ageing is a physiological process, it is recognized that extrinsic variables like air pollution, alcohol use, and UV exposure have a negative impact on skin cells and contribute to accelerated ageing. By helping to maintain moisture and a young glow, Anti Aging creams and lotions are essential in a person's life. In 2020, a Real Self poll found that 62% of Americans included Anti Aging products in their regular skincare routine.

Anti Aging Products and Therapies Market: Impacting Factors

A major factor driving Anti Aging Products and Therapies Market is the rise in skin cancer cases. The advent of Anti Aging therapies including breast implants, plastic surgeries, etc. as a consequence of major technology advancements and increasing R&D activity has fueled market expansion.

Increased awareness of ageing among young people and adults in relation to their physical looks has also contributed to the product's soaring demand. However, the expense of the goods and the dangers associated with hazardous Anti Aging therapies are expected to impede the Anti Aging Products and Therapies Market's growth.

Get Access to sample Report Pages of Anti Aging Products and Therapies Market: -

https://www.pharmaresearchconsulting.com/reports/anti-aging-products-and-therapies-market-growth-trends-and-forecast-by-type-human-growth-hormone-stem-cell-placenta-by-application-anti-pigmentation-therapy-anti-cellulite-treatment-anti-wrinkle-treatment-and-by-regions/inquiry

Anti Aging Products and Therapies Market: Recent Development

Anti Aging Products and Therapies Market Key Players:

Anti Aging Products and Therapies Market Major Key Players include: Allergan, Ipsen, Lanzhou Institute, Corneal(Allergan), Galdermal, LG Life Science, Bohus BioTech, IMEIK, Merck, Gaoxin, Others.

Browse Complete Premium Report for Anti Aging Products and Therapies Market: https://www.pharmaresearchconsulting.com/reports/anti-aging-products-and-therapies-market-growth-trends-and-forecast-by-type-human-growth-hormone-stem-cell-placenta-by-application-anti-pigmentation-therapy-anti-cellulite-treatment-anti-wrinkle-treatment-and-by-regions

Anti Aging Products and Therapies Market: Growth Factors

An intricate biological process, skin ageing is influenced by both internal and external factors. Women seem to favour Anti Aging products the most. Women place a lot of importance on having beautiful skin and being healthy. As a result, several Anti Aging treatments and procedures have been introduced during the past ten years. People are increasingly more conscious about their skin and health today. Additionally, the physical appearance is given the highest significance. A person with a positive personality is also admired by everyone. All of the aforementioned variables together are resulting in a demand for Anti Aging Products and Therapies Market.

Anti Aging Products and Therapies Market:Segmentation

By Type, it is segmented into

By Application, it is segmented into

Anti Aging Products and Therapies Market: Regional Analysis

The market in North America held the largest market share in 2020 and is anticipated to expand at a consistent CAGR throughout the course of the forecast period. This might be linked to the region's ageing population, particularly generation Y, which is driving industry growth by being increasingly concerned of wellbeing, attractiveness, and physical appearance.

The existence of major Anti Aging Products and Therapies Market participants, increased knowledge of plastic surgery, the availability of well-established infrastructure, and rising buying power all contribute to the region's growth.

Browse MorePharmaceutical Market Reports

Osteoarthritis Pain Drugs Market

Osteoarthritis Pain Drugs Market will register a CAGR of 6.1 % in terms of revenue and the global market size will reach USD 13.8 Billion by 2029.

https://www.pharmaresearchconsulting.com/reports/osteoarthritis-pain-drugs-market-growth-trends-and-forecast-2022-2029-by-drug-class-nsaids-opioids-viscosupplements-corticosteroids-and-others-route-of-administration-oral-parenteral-and-topical-and-by-regions

Stable Isotope Labeled Biomolecules Market

The use of stable isotopically labelled biomolecules is a crucial technique for determining high-resolution structures for NMR spectroscopy. The user can greatly simplify their spectra by either evenly or selectively introducing stable isotopes into proteins.

https://www.pharmaresearchconsulting.com/reports/stable-isotope-labeled-biomolecules-market-growth-and-forecast-2022-2029-by-type-d-labeled-biomolecules-15n-labeled-biomolecules-13c-labeled-biomolecules-by-application-scientific-research-medical-industrial-and-by-regions

Microbial Fermentation APIs Market

Microbial Fermentation APIs Market will register a CAGR of 1.2 % in terms of revenue and the global market size will reach USD 32 Billion by 2029.

https://www.pharmaresearchconsulting.com/reports/microbial-fermentation-apis-market-growth-trends-and-forecast-2022-2029-by-type-antibiotics-amino-acids-nucleotide-alcohol-biological-products-by-application-hospitals-research-academic-laboratories-and-by-regions

Insulin Market

The rise in the prevalence of diabetes, increased government backing, increased financing for R&D, and technical developments all contribute to the growth of the worldwide insulin market. Additionally, R&D efforts in the insulin industry are increasing as scientists worldwide work to create an improved insulin molecule for diabetic patients that boosts effectiveness and reduces negative effects.

https://www.pharmaresearchconsulting.com/reports/insulin-market-growth-trends-and-forecast-2022-2029-by-product-type-intermediate-acting-insulin-short-acting-insulin-long-acting-insulin-by-source-human-recombinant-insulin-insulin-analogs-and-by-regions

Insulin API Market

Insulin is a crucial medication used to treat patients with diabetes. It is used to treat people with both type 1 and type 2 diabetes, where type 1 diabetes is a disease in which the body does not produce insulin, and type 2 diabetes is brought on by the body's inability to effectively utilize insulin, which leads in an inability to manage blood sugar levels.

https://www.pharmaresearchconsulting.com/reports/insulin-api-market-global-growth-trends-and-forecast-2022-2029-by-type-regular-human-insulin-insulin-analogue-others-by-end-user-fast-acting-long-acting-premix-and-by-regions

Link:

Anti Aging Products and Therapies Market rocket up to USD 3.3 Billion by 2029 at a 8% CAGR Check Industry Share, Growth, Analysis, Value, Statistics -...

6 Signs You’re Aging Faster Than You Should Eat This Not That – Eat This, Not That

Aging is a part of life that we can't do anything about, but we can slow it down or speed it up depending on our lifestyle choices and health habits. In addition to prematurely aging, certain health issues can arise causing the process to accelerate and Eat This, Not That! Health spoke with experts who share signs you're aging faster than you should that you need to be aware of. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Tomi Mitchell, a Board-Certified Family Physician with Holistic Wellness Strategies shares, "I have yet to meet an adult who has told me they want to age quickly. The fact is, many people start to become acutely aware of their age after they hit 30. They begin to see the first signs of wrinkles and gray hair and feel aches and pains in their joints. As a result, they begin to feel like they are losing their youth and vitality. For many people, this can be a very unsettling experience. They may spend more time and money on beauty products and cosmetics to hold on to their child. They may also try to change their lifestyle habits to stay healthy and fit. However, the sad truth is that there is no turning back the clock. Aging is an inevitable part of life. However, that does not mean that we have to give in to it without a fight. By caring for our bodies and minds, we can still enjoy a high quality of life as we age. So, even though we cannot stop the aging process, we can certainly slow it down. However, there are signs that you may be aging faster than you should. You should talk to your doctor if you notice any of the following symptoms."

Lisa Richards, a nutritionist and author of the Candida Diet tells us, "For most individuals chronic pain and inflammation is not a normal part of everyday life. If you find yourself experiencing inflammation, water retention, poor sleep, and chronic pain you are likely aging faster than you should. For those without a medical diagnosis to explain these symptoms, the culprit is likely the foods you are choosing to fuel your body with. Cutting down on saturated fats, refined carbohydrates, added sugar, and other inflammatory foods can help slow down this process and lessen these side effects. Choosing to take in anti-inflammatory foods can also slow down the aging process by feeding your body antioxidant rich foods, whole grains, and healthy fats. This leads to better cellular health, gut health, immunity, and overall wellness."

"Did you know that loss of muscle mass could signify that you are aging faster than you should be?" Dr. Mitchell asks. "It's true! Muscle mass begins to decline around 30, which accelerates as we age. There are several reasons for this, including a decrease in the production of hormones such as testosterone and growth hormone and a reduction in the number of muscle cells. This process can be accelerated by poor nutrition, lack of exercise, and certain medications. However, some ways to slow down muscle loss include regular exercise, adequate protein intake, and supplementation with creatine or other nutrients. So if you're concerned about losing muscle mass, take action today to keep your body young and strong."

6254a4d1642c605c54bf1cab17d50f1e

According to Dr. Mitchell, "One of the most visible signs of aging is a change in the appearance of the skin. As we age our skin becomes thinner and less elastic, leading to wrinkles, age spots, and dryness. While this is a natural part of the aging process, it can be accelerated by environmental factors such as sun exposure and smoking. Additionally, lifestyle choices, such as a poor diet or not getting enough exercise, can contribute to premature aging. If you notice your skin showing signs of aging, it's essential to take steps to protect it from further damage. This includes sunscreen outdoors, quitting smoking, and eating a healthy diet. These steps will help you keep your skin looking its best for years."

Dr. Mitchell reminds us, "As we age, our bodies go through a lot of changes. One of the most noticeable changes is the way our bones change. Over time, our bones become weaker and more brittle. This is a natural part of the aging process, but it can signify that we are aging faster than we should be. Our bones are constantly breaking down and rebuilding themselves, but as we age, the rate at which they break down begins to exceed the rate at which they rebuild themselves. This can lead to decreased bone density and an increased risk of fractures. Several factors can contribute to this process, including a lack of exercise, a poor diet, and certain medical conditions. If you are concerned about your bone health, speak to your doctor about ways to slow down the aging process."

"When it comes to hair loss, there can be many different causes," Dr. Mitchell states. "However, one potential reason is accelerated aging. Hair loss is a normal part of the aging process, as hair follicles gradually produce more delicate and weaker strands of hair. However, losing a large amount of hair could signify that you are aging faster than you should be. Several possible reasons include hormonal imbalances, vitamin deficiencies, and stress. If you are concerned about accelerated aging, you must consult a doctor or dermatologist. In addition, they will be able to assess your case and provide guidance on how to proceed."

Dr. Mitchell states, "There's no getting around it: as we get older, our bodies change. We don't have the same energy levels we did when we were young, and we start to see the effects of time in the form of wrinkles and gray hair. But did you know that insomnia is one of the earliest signs of aging? That's right: if you're having trouble sleeping, it could signify that you are aging faster than you should be. Several factors can contribute to insomnia, but as we age, our bodies produce fewer hormones that help us sleep soundly. In addition, many medications that are commonly prescribed to seniors can have side effects that make it difficult to fall asleep or stay asleep through the night. And if that weren't enough, aging also increases our risk for medical conditions like Alzheimer's disease and Parkinson's disease, which can cause sleep problems. If you're having trouble sleeping, you should talk to your doctor. There are treatments available that can help you get the rest you need, and by addressing your insomnia, you may be able to slow down the aging process. So don't wait: if you're not getting enough shut-eye, make an appointment with your doctor today.

Dr. Mitchell says this "doesn't constitute medical advice and by no means are these answers meant to be comprehensive. Rather, it's to encourage discussions about health choices."

Read the rest here:

6 Signs You're Aging Faster Than You Should Eat This Not That - Eat This, Not That

Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight – PR Newswire

The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of complicated urinary tract infection. Leading companies like Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, and others are developing drugs for complicated urinary tract infection treatment.

LAS VEGAS, Sept. 12, 2022 /PRNewswire/ --DelveInsight's Complicated Urinary Tract Infections Market Insights report includes a comprehensive understanding of current treatment practices, complicated urinary tract infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Complicated Urinary Tract Infections Market Report

Discover which therapies are expected to grab major complicated urinary tract infections market share @Complicated Urinary Tract Infections Market Report

Complicated Urinary Tract Infections Overview

Urinary tract infections (UTIs) are among the most common bacterial infections. Clinically, they can manifest in various ways, ranging from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a multifaceted entity with numerous forms. Infection from microorganisms is among the major complicated urinary tract infections causes.

Complicated urinary tract infection symptoms such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort are the most important clinical criteria for the initial complicated urinary tract infection diagnosis. Furthermore, there must be a suitable clinical scenario in which the most likely cause of these complicated urinary tract infection symptoms is a urogenital tract infection.

The complicated urinary tract infections treatment goals are to eliminate the infection, avoid complications, and provide symptomatic relief. Early complicated urinary tract infection treatment is recommended to reduce the risk of developing pyelonephritis.

Complicated Urinary Tract Infections Epidemiology Segmentation

As per DelveInsight, there were approximately 8 million complicated urinary tract infections diagnosed incident casesin the 7MM in 2021.

Among the 7MM, the US had recorded the highest diagnosed incidence of complicated urinary tract infectionsin 2021.

The complicated urinary tract infections market reportproffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving complicated urinary tract infections epidemiology trends @Complicated Urinary Tract Infections Epidemiological Insights

Complicated Urinary Tract Infections Treatment Market

Complicated UTIs are treated with broader antimicrobial coverage and may require intravenous antibiotics depending on severity. For difficult lower UTIs, broad-spectrum antibiotic therapy should be used for 714 days and curable underlying causes should be treated. Recurrent UTIs are common in women, and antibiotic prophylaxis may be recommended. Catheter-associated urinary tract infection (CAUTI) is one of the most common infections associated with healthcare, and it is treated with catheter removal or replacement as well as antibiotic medication. CAUTIs are frequently caused by resistant bacteria. Pregnant women should be tested and treated for UTIs and asymptomatic bacteriuria, respectively.

Moreover, Avycaz was approved in the United States in February 2015 for the treatment of adult patients with complex urinary tract infections (cUTI), including pyelonephritis, caused by identified susceptible bacteria such as certain Enterobacteriaceae and Pseudomonas aeruginosa. It was approved in Europe in June 2016. The company expanded its label for pediatric patients in the US market in March 2019 and in Europe in November 2020. Allergan and Abbvie have US rights to the drug's development, while Pfizer has market rights outside of the US. The only drugs approved for adult and pediatric patient pools are Zerbaxa and Avycaz. Other drugs approved by the FDA and EMA for complicated urinary tract infection treatment include Recarbrio (Merck), Fetroja (Shionogi), Vabomere (Melinta therapeutics), and Zemdri (Cipla therapeutics).

To know more about complicated urinary tract infections treatment options, visit @New Treatment forComplicated Urinary Tract Infections

Complicated Urinary Tract Infections Pipeline Therapies and Key Companies

Learn more about the complicated urinary tract infectionstherapies in clinical trials @Drugs forComplicated Urinary Tract Infections Treatment

Complicated Urinary Tract Infections Market Dynamics

With increasing multidrug resistance and antibiotic overuse, the prevalence of cUTIs is expected to rise in the future, propelling the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for cUTI is expected to aid complicated urinary tract infections market growth.

Moreover, antibiotics are in high demand as they are the only treatment for cUTIs and UTIs. There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market. Furthermore, increased mergers/acquisitions and collaborations between companies to develop safe and effective drugs will accelerate complicated urinary tract infections market growth.

However, inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus impeding the growth of the complicated urinary tract infections market.

Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to impede clinical trial study evaluation in the complicated urinary tract infections market.

As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis, complex regulatory requirements are expected to hinder the growth of the complicated urinary tract infections market.

Furthermore, conflicting guidelines on uncomplicated urinary tract infections issued by various organizations cause confusion among providers that will further impact the growth of the complicated urinary tract infections market.

Scope of the Complicated Urinary Tract InfectionsMarket Report

Discover more about drugs for complicated urinary tract infectionsin development @Complicated Urinary Tract Infections Clinical Trials

Table of Contents

1.

Complicated Urinary Tract Infections Market Key Insights

2.

Complicated Urinary Tract Infections Market Report Introduction

3.

Complicated Urinary Tract Infections Market Overview at a Glance

4.

Complicated Urinary Tract Infections Market Executive Summary

5.

Disease Background and Overview

6.

Complicated Urinary Tract Infections Treatment and Management

7.

Complicated Urinary Tract Infections Epidemiology and Patient Population

8.

Patient Journey

9.

Complicated Urinary Tract Infections Marketed Drugs

10.

Complicated Urinary Tract Infections Emerging Drugs

11.

Seven Major Complicated Urinary Tract Infections Market Analysis

12.

Complicated Urinary Tract Infections Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Complicated Urinary Tract Infections Market Drivers

16.

Complicated Urinary Tract Infections Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Get in touch with our business executive@Healthcare Due Diligence Services

Related Reports

Complicated Urinary Tract Infections Epidemiology Forecast

Complicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the complicated urinary tract infectionsepidemiology trends.

Complicated Urinary Tract Infections Pipeline

Complicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key complicated urinary tract infections companies, including Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, among others.

Uncomplicated Urinary Tract Infections Pipeline

Uncomplicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key uncomplicated urinary tract infections companies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Market

Uncomplicated Urinary Tract InfectionsMarket Insights, Epidemiology, and Market Forecast 2032report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key uncomplicated urinary tract infectionscompanies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Epidemiology

Uncomplicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the uncomplicated urinary tract infectionsepidemiology trends.

Other Trending Reports

Diagnostic Imaging Equipment Market|Invasive Candidiasis Market| Sialidosis Market| Filgrastim Biosimilar Insight| Pain Management Devices Market| Primordial Dwarfism Market| Non-cystic Fibrosis Bronchiectasis Market| Microsatellite Stable Colorectal Cancer Market| Cystinuria Market| Deep Vein Thrombosis Market| Acquired Immunodeficiency Syndrome Market| Gene and Cell Therapies in Rare Disorder Market| Pediatric Growth Hormone Deficiency (PGHD) Market|Pain Management Devices Market| Diagnostic Imaging Equipment Market| Ischemic Stroke Market| Paget's Disease Market| Resorbable Vascular Scaffold Market| RosaiDorfman disease (RDD) Market| Salivary Gland Infection Market| Sandhoff Disease Market| Scedosporium Infection Market| Structural Heart Devices Market| Vascular Graft Devices Market| Vascular Stents Market| Vein Illumination Devices Market| Ventricular Assist Devices (VAD) Market| Adrenocortical Carcinoma Market| Cystinuria Market| Myopia Treatment Devices Market| Urology Ultrasounds Devices Market| Sly Syndrome Market| Human Papillomavirus-Positive Oropharyngeal| Cancer Market| Tuberculosis Market| Plasmodium Vivax Malaria Market| Oncolytic Virus Cancer Therapy Pipeline| Facial Lines Market| Rosacea Market| Polycystic Kidney Disease Market| Oropharyngeal Cancer Market| NPC Market| Immune Thrombocytopenia Market

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

Connect with us onLinkedIn|Facebook|Twitter

Contact Us:Shruti Thakur [emailprotected]+1(919)321-6187www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

Read more:

Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight - PR Newswire

Triple-Negative Breast Cancer Treatment Market to Experience Significant Growth During the Forecast Period 2026 – BioSpace

Wilmington, Delaware, United States, Transparency Market Research Inc. Triple-negative breast cancer (TNBC) doesnt have estrogen or progesterone receptors and also doesnt make too much of the HER2 protein. Because the cancer cells lack these proteins, hormone therapy and drugs that target HER2 are not helpful, so chemotherapy (chemo) is the main systemic treatment option. And although TNBC tends to respond well to initial chemo, it tends to come back (recur) more frequently than other breast cancers.

Read Report Overview https://www.transparencymarketresearch.com/triple-negative-breast-cancer-treatment-market.html

If the early-stage TNBC tumor is small enough to be removed by surgery, then breast-conserving surgery or a mastectomy with a check of the lymph nodes may be done. In certain cases, such as with a large tumor or if the lymph nodes are found to have cancer, radiation may follow surgery.

Because hormone therapy and HER2 drugs are not good options for women with TNBC, chemotherapy is the main systemic option. It might be given before surgery (neoadjuvant chemotherapy) to shrink a large tumor. If cancer is still found after neoadjuvant chemo has been given, the doctor may recommend to take an oral chemo drug called capecitabine for 18 to 24 weeks. A pateint might also be given chemo after surgery (adjuvant chemotherapy) to reduce the chances of the cancer coming back.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Overview

The global triple-negative breast cancer treatment market is projected to witness a promising growth in the coming few years. The rising number of breast cancer cases and the advancements in the medical sector holds immense growth potential in the coming few years. The research study on the triple-negative breast cancer treatment market offers a detailed study, highlighting the key segmentation, regional outlook, and the competitive landscape.

Global Triple-Negative Breast Cancer Treatment Market: Key Trends

The rising focus of the players on the research and development activities for therapies and drugs for rare diseases is estimated to create a huge opportunity, thus supporting the growth of the market. The high number of clinical trials for the combination therapies and the increasing number of collaborations and mergers are predicted to encourage the market growth throughout the forecast period.

Request for ToC https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=50904

Furthermore, the presence of a robust pipeline of drugs in the clinical development so as to treat breast cancers is another key factor predicted to drive the global triple-negative breast cancer treatment market in the near future.

Global Triple-Negative Breast Cancer Treatment Market: Market Potential

Triple-negative breast cancer treatment is majorly treated with a combination of therapies, including radiation therapy, surgery, and chemotherapy. Several research studies have stated that hormone-receptor-negative breast cancers have responded effectively to chemotherapy in comparison with the breast cancers that are hormone-receptor-positive. The advent of new and effective treatments and the rising awareness among people concerning the lifestyle changes that are required to be made are likely to bid potential development opportunities for the key players in the forecast period.

Request for Report Methodology https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Regional Outlook

Among the key regional segments, North America is projected to account for a massive share of the market in the next few years. The presence of several leading players and the availability of advanced healthcare infrastructure are expected to support market growth in the near future. Moreover, the investments by private and government organizations for research activities is expected to enhance the market growth in the coming years.

Furthermore, Asia Pacific is predicted to witness high growth, thanks to the rising contribution from India and China. In addition, the rising prevalence of triple-negative breast cancer and the increasing treatment rate are likely to augment market growth in the near future.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=50904

Global Triple-Negative Breast Cancer Treatment Market: Competitive Analysis

The global market for triple-negative breast cancer treatment market is competitive in nature with a presence of several players operating worldwide. The key focus of the players on research and development activities, along with technological advancements in the medical sector are estimated to support the market growth in the forecast period.

In addition to this, the development of new and effective drugs and therapeutics is projected to offer growth opportunities for players in the near future. Some of the key players operating in the triple-negative breast cancer treatment market across the globe are Mylan N.V., Sanofi S.A., Celgene Corporation, F. Hoffman - La Roche Ltd., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer, Inc., and Johnson & Johnson Services, Inc.

More Trending Reports by Transparency Market Research

Medical Device Technologies Market: The global medical device technologies market is expected to reach the value of US$ 662.7 Bn by the end of 2028.

Animal Healthcare Market: The global animal healthcare market is expected to cross the value of US$ 63.2 Bn by the end of 2028.

Erectile Dysfunction Drugs Market: The global erectile dysfunction (ED) drugs market is expected to reach the value of US$ 2.5 Bn by the end of 2028.

Regulatory Affairs Outsourcing Market: The global regulatory affairs outsourcing market is expected to reach the value of US$ 17.3 Bn by the end of 2028.

Digital Health Market: The global digital health market is expected to cross the value of US$ 1.2 Trn by the end of 2028.

Equine Healthcare Market: The global equine healthcare market is expected to cross the value of US$ 972.8 Mn by the end of 2028.

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.

Medical Imaging Equipment Market: The global medical imaging equipment market is expected to reach the value of US$ 50.3 Bn by the end of 2028.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, providescustom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.com

Blog: https://tmrblog.com

Email: sales@transparencymarketresearch.com

Link:

Triple-Negative Breast Cancer Treatment Market to Experience Significant Growth During the Forecast Period 2026 - BioSpace

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the…

- Company to host Key Opinion Leader webinar today, September 12, at 1:30 pm CT/2:30 pm ET -

LYON, France and CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP-3601 in patients with hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR), which is being held September 9-12 in Austin, TX.

During three months of treatment with AZP-3601, mean serum calcium levels were maintained within the target range and allowed for the discontinuation of oral calcium and active vitamin D supplementation in most patients. Normalization of urinary calcium was rapidly achieved in all patients, including those with hypercalciuria at baseline, together with restoration of balanced bone resorption/formation activity. AZP-3601 was well tolerated and demonstrated a favorable safety profile.

We are very pleased with the compelling results from the first patient cohort of this ongoing trial, said Mark Sumeray, M.D., chief medical officer of Amolyt Pharma. The data demonstrate that the mechanism of action of AZP-3601 translates into important potential clinical benefits for patients with hypoparathyroidism, in particular those with or at risk of developing hypercalciuria, osteopenia or osteoporosis, who represent the majority of patients with this disease. We look forward to results from Cohort 2, which will inform the design of a Phase 3 trial as we work to advance this promising therapeutic peptide through an efficient late-stage development plan.

Key findings:

The study was a three-month multi-center open-label design. Following an optimization period of up to eight weeks during which calcium and active vitamin D supplementation were adjusted to achieve baseline albumin-adjusted serum calcium (AdsCa) within the range of 7.8 to 9.0mg/dL, patients received a daily subcutaneous (sc) administration of 20g AZP-3601 for 28 days, while simultaneously reducing their calcium and active vitamin D intake. Further up-titration to a maximum dose of 60 g/d was recommended if needed to achieve AdsCa within the target range.

Thierry Abribat, Ph.D., founder and chief executive officer of Amolyt Pharma, added, With AZP-3601, our key underlying assumption is that intermittent administration of this PTH analog targeting the R0 conformation of the PTH receptor would induce a long-acting effect on serum Ca, mainly through a potent and sustained effect on Ca reabsorption in the kidney, while stimulating resumption of normal bone metabolism, thus preserving bone minerality. These data support this assumption, outlining a potentially new clinical profile, which we believe is ideally suited to address the needs of patients with hypoparathyroidism.

Oral Presentation Details:Title: Efficacy and Safety of AZP-3601, a Novel Investigational Long-Acting PTH Analog for Treatment of Hypoparathyroidism. Results From the First Cohort of a 3-Month Multi-Center Open Label Phase 2a StudyFormat: Late-breaking oral presentationDate: Monday, September 12, 2022Session time: 11:30 am-12:45 pm CT (12:30 pm-1:45 pm ET)Presentation time: 11:30 am-11:45 am CT (12:30 pm-12:45 pm ET)Author/Presenter: Istvan Takcs, M.D. (Semmelweis University, Budapest, Hungary), author and lead investigator of the study

Investor webinar:Amolyt will host a KOL webinar to discuss these Phase 2a results in more detail today, September 12, 2022, at 1:30 pm CT/2:30 pm ET. Interested parties can register for the webinar here.

About Hypoparathyroidism Hypoparathyroidism is defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood. Approximately 80% of the estimated 80,000 people in the U.S. and 110,000 in the European Union with hypoparathyroidism are women. Despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. Clinical manifestations of hypoparathyroidism impact many tissues and organ systems, in particular, the kidneys and bone. 17% of patients with hypoparathyroidism have osteopenia or osteoporosis and 53% are peri- or postmenopausal women with an increased risk of developing osteoporosis. Approximately 26% of patients with hypoparathyroidism have chronic kidney disease or failure, highlighting the importance of reducing urinary calcium excretion as a key treatment goal.

About AZP-3601AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing chronic kidney disease. In addition to its unique receptor profile, AZP-3601 is also designed to have a short half-life to potentially preserve bone integrity, an important benefit, since many patients are peri- and postmenopausal women with an increased risk of developing osteoporosis.

About Amolyt PharmaAmolyt Pharma, a clinical stage biotechnology company, is building on its teams established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.

Go here to read the rest:

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the...

Like it or not, e-bikes on Hilton Head are here – Charleston Post Courier

HILTON HEAD ISLANDPeople move to Hilton Head for all kinds of reasons. The beach, the golfing, the weather. Parker Wood came for the bike paths.

"Me being able to get around on a bicycle and having my independence was a big key," said Wood, 20. Because he was born before his eyes fully developed, he doesn't see perspective well enough to drive.

But he can hop on two wheels and zip the 18 miles to and from his two jobs busing tables and prepping drinks at restaurants. When Wood flips on his e-bike's pedal assist, the commute is both quicker and easier.

"My e-bike is my car," he said.

Parker Wood is seen in his reflector setting up the gadgets needed to ride his electric bike to work on Aug. 31, 2022, on Hilton Head. Wood uses his bike as his main form of transportation due to limited vision going between work and the gym routine. Andrew J. Whitaker/Staff

Not everyone is enthusiastic about sharing Hilton Head with e-bikes, which are heavier and can be faster than conventional bicycles.

But last month Town Council passed 5-1 an ordinance allowing them on the town's 64 miles of public pathways.

The one dissenting voter, Tamara Becker, told The Post and Courier the island has not figured out a way to ensure everyone's safety.

"If you don't have a solution that works, you don't put something on paper and call it a day," Becker said.

Small motorized vehicles are still not allowed on pathways.

However, for advocates the vote to allow e-bikes is not just a concession to South Carolina law, which considers"electric-assist bicycles" and "bicycles with helper motors" simply bicycles, not mopeds. Instead, enthusiasts like Wood hope the new ordinance ushers in a future in which e-bikes are a permanent part of the island's transportation ecosystem.

Parker Wood waves to a motorist while commuting to work on his electric bike on Aug. 31, 2022, on Hilton Head Island. Andrew J. Whitaker/Staff

Frank Babel, 80, is known for two things: biking and persistence.

When he retired to Hilton Head in 2004 he was appalled by its infrastructure for cycling. So he started a group called Squeaky Wheels.

"I was the guy who went to these meetings in the Town Hall and said 'You know, your maintenance is terrible. The pathways are dirty. We have no maps. How do you get across the street safely?'"

Eventually, he persuaded officials to his cause. The town invested in crosswalks, traffic signals and safety islands. It widened the pathways and added more of them.

Today a cyclist on Hilton Head can get pretty much anywhere on a paved trail that winds around neighborhoods and resorts, over wooden bridges and under tree canopies. Crashes have also gone down.

Thanks in large part to Babel and his organization, which morphed into Bike Walk Hilton Head Island, the League of American Bicyclists has three times named the island aBike Friendly Community.

Babel's success offers both an example of how the island can evolve and an explanation for why e-bikers want to come here.

"We plan (our vacations) around bike paths," said Deb Camp, 68, who'd come to Hilton Head from Florida with her husband, Warren Camp, 74. "He's enjoying it. We're getting out of the house."

Parker Wood rides down a bike path from work on Aug. 31, 2022, on Hilton Head Island. Andrew J. Whitaker/Staff

The Camps are exactly the kind of people e-bike advocates say the vehicles stand to benefit: those who wouldn't otherwise be able to ride.

"I'd gotten injured in the service and broke my back," said Warren Camp, who keeps a Vietnam Vet cap dangling from his bike frame. "Then I drove an e-bike in Fort Myers, and it changed my life forever."

Compared with a regular bike, Camp says e-bikes are more comfortable and easier to ride. He uses the pedal-assist feature "so I'm able to go twice, three times the distance without using a throttle," he said.

Camp pointed to a speedometer on the handlebar that shows how fast he's going usually around 11 mph on Hilton Head's pathways, he said.

And if he encounters walkers or slower-moving bikers on the trail?

Camp touched a lever and made a cheery ding. "Everybody likes a little bell," he said.

Jim Hall, owner of Hilton Head Electric Bicycle Co., wheels out one of the electric bikes from his shop on Aug. 31, 2022, in Hilton Head. Hall said recently electric bikes have been becoming more popular on the island as prices have been going down. Andrew J. Whitaker/Staff

The owner of Hilton Head Electric Bicycle Co., Jim Hall, said he sees a lot of folks like the Camps.

"The vast majority of (e-bike renters) were the older demographic," said Hall, who began building his fleet of e-bikes shortly after he and his wife bought the company in 2020. "Spouses that wanted to ride together, people with new hips and knees. ... We've outfitted bikes to allow folks to put their crutches on them."

The data the Halls collected from about 500 e-bike customers belied an image of buzzing swarms of young people tearing around the island; instead, "we had more people in their 80s than their 20s," Hall said.

Still, he acknowledged that some people react negatively to the sight of an e-bike. For someone used to the slender silhouette of a road bike or the easy-going attitude of a beach cruiser, e-bikes can appear like they've been injected with a growth hormone. Their tires are bigger and fatter, and the ones in Hall's shop can weigh 70 pounds.

"In fairness, people who are anti e-bike have concerns about colliding with someone on that," Hall said.

But e-bikes are not going away, at least as far as Hall can see. "There's more of them on the island every day, whether we're selling them or people are ordering them off of Amazon," he said.

The Halls do such a brisk business that they operate two separate shops now, what they call "the electric side" and "the acoustic side." The electric side makes more money.

"We've been blown away," Hall said. Ranging from about $1,000 to almost $4,000, his e-bikes both cost more and sell better.

Even he and his wife own a pair. With parking and traffic being such an issue on Hilton Head "it's a beautiful way to get around and go out," he said.

While e-bike enthusiasts can speak glowingly about their benefits for commuters, parents, people with disabilities, the environment the person responsible for dealing with collisions, the town'snew director of Public Safety, offered a more matter-of-fact perspective.

"I've been working (on Hilton Head Island) for over 30 years," said Bob Bromage. "I can assure you there have been numerous accidents involving bicycles and vehicles."

The way forward, Bromage said, is education.

On that assertion, he aligns both with the town's new ordinance, which requires anyone who rents or sells an e-bike to provide safety information, and with the national Bicycle Friendly America Program.

Amelia Neptune, who directs the program, said the organization now takes receptiveness to e-bikes into account when making Bicycle Friendly Community awards, which Hilton Head will apply for again in 2023.

"We want to see a community ... allowing e-bikes anywhere a bike would be, but coupling that with education," Neptune said.

For example, e-bike riders should know trail etiquette, how to be audible as they're passing, and why it's important to go at a reasonable speed.

Neptune pointed out that on a road with cars, bikers are at risk. On a trail with e-bikes, pedestrians are at risk. In either of those situations, education protects the most vulnerable.

In addition, town staff are looking at structural ways to enhance safety, said community planning manager Missy Luick. Those elements might include signs, rights of way, and centerline striping.

E-bikes are here already, Luick said. Insofar as the number and range of people using Hilton Head's pathways present difficulties, she said, "they're all good problems to have."

View post:

Like it or not, e-bikes on Hilton Head are here - Charleston Post Courier

Ribociclib Can Add Almost 1 Year to Overall Survival for Patients With Aggressive Form of Breast Cancer – Pharmacy Times

Ribociclib with endocrine therapy was found to increase the median overall survival of patients with HR+/HER2- advanced breast cancer with visceral metastases to nearly 5 years.

Ribociclib (Kisqali; Novartis) was found to add nearly 1 year to overall survival (OS) in patients with aggressive hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC).

In a pooled exploratory analysis of the MONALEESA phase 3 program presented at the 2022 European Society of Medical Oncology Congress (ESMO), researchers found that first-line treatment with ribociclib and endocrine therapy increased the median OS by 10.6 months, compared to endocrine therapy alone.

Patients who have visceral metastases typically have a worse prognosis and often demonstrate resistance to treatment, so as a clinician it is encouraging to see significant survival benefit with ribociclib in the first-line setting in patients with more aggressive disease, said Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, in a press release.

Ribociclib, a CDK4/6 inhibitor, is the only inhibitor that was found to benefit the OS of patients with HR+/HER2- aBC in all its phase 3 trials. National Comprehensive Cancer Network (NCCN) guidelines also recognize ribociclib as the only CDK4/6 inhibitor to benefit OS in patients with HR+/HER2- aBC.

The subgroup of patients with this aggressive form of aBC may have visceral metastases on the liver. Compared to endocrine therapy as a sole first-line treatment, ribociclib plus endocrine therapy increased the median OS from 38.1 months to 44.2 months.

Further, among patients who have 3 or more organs with visceral metastases, first-line treatment with ribociclib and endocrine therapy increased the median OS by 8.4 months compared to endocrine therapy alone, with the median OS rising from 49.3 months to 57.7 months.

According to Magnitude of Clinical Benefit Scale, which was created by ESMO, ribociclib had the highest ratings out of every CDK4/6 inhibitor on the scale.

Ribociclib is the only CDK4/6 inhibitor to show a consistent overall survival benefit in combination with endocrine therapy, while also maintaining quality of life across the phase 3 program, Yardley said in the press release.

Ribociclib, combined with an aromatase inhibitor or fulvestrant, is approved by the FDA as a first-line endocrine-based therapy for HR+/HER2- advanced or metastatic breast cancer. It has also been approved in more than 95 countries worldwide.

The goal for advanced breast cancer treatment is to help people live longer, and we are proud that Kisqali continues to deliver a significant survival benefit while also maintaining quality of life, even for those with harder-to-treat disease, said Jeff Legos, executive vice president, global head of Oncology and Hematology at Novartis, in the press release. We are committed to demonstrating what makes Kisqali a unique CDK4/6 inhibitor, thus providing patients and oncologists confidence in this therapeutic option.

Reference

Novartis. Novartis Kisqali adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer. Novartis website. September 9, 2022. Accessed on September 9, 2022. https://www.novartis.com/news/media-releases/novartis-kisqali-adds-one-more-year-survival-benefit-broadest-set-patients-including-those-aggressive-hrher2-advanced-breast-cancer

More:

Ribociclib Can Add Almost 1 Year to Overall Survival for Patients With Aggressive Form of Breast Cancer - Pharmacy Times